HK inno.N Corp

South Korean pharmaceutical company headquartered in Seoul with plants at Daejeon and Icheon, formed when the pharmaceutical business of CJ HealthCare was bought by the Korea Kolmar group in 2018 and renamed HK inno.N in 2020. Develops, manufactures and markets prescription medicines, best known for tegoprazan, a potassium competitive acid blocker sold as K-CAB and licensed to partners in many countries, together with vaccines, infusions, biosimilars and health functional foods and beverages.